Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseChronic Myelomonocytic LeukemiaMyelodysplastic NeoplasmsSubgroupICD10C93.1-D46.-MeSHLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesSequenceChemotherapyChemo-substanceDecitabine-CedazuridineHydroxyureaRuxolitinibChemo-substanceDecitabine-CedazuridineHydroxyureaRuxolitinibChemo-substanceDecitabine-CedazuridineHydroxyureaRuxolitinibChemo-substanceDecitabine-CedazuridineHydroxyureaRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleSupportive substanceCiprofloxacinGranisetronPosaconazoleNo. Substances3Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlBleedingCardiotoxicityEmetogenicityEmetogenicity (ASCO)Febrile NeutropeniaInfectionsLeukopeniaNeutropeniaPneumoniaSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorGarcia-Manero GHunter AMItzykson RDiseaseChronische Myelomonozytäre Leukämie, Erstline, ECOG 0-2CMML (WHO 2016)Myelodysplastisches Syndrom und chronische myelomonozytäre Leukämie, ECOG 0-2OriginDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXHopital Saint-Louis, Assistance Publique-Hopitaux de Paris, Paris, France, DACOTA trialWinship Cancer Institute, Emory University School of Medicine, Atlanta, GeorgiaProtocols in Revision 3 protocols foundProtocols under revision.Decitabine-Cedazuridine 135, Myelodysplastic Syndrome (PID2514 V1.0)Hydroxyurea 1000, Chronic Myelomonocytic Leukemia (PID2300 V1.0)Ruxolitinib 20, Chronic Myelomonocytic Leukemia (PID2319 V1.0)
